Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $15.0 million.

  • Voyager Therapeutics' Accumulated Expenses rose 3068.52% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 3068.52%. This contributed to the annual value of $14.2 million for FY2024, which is 1576.41% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Accumulated Expenses of $15.0 million as of Q3 2025, which was up 3068.52% from $12.0 million recorded in Q2 2025.
  • Voyager Therapeutics' Accumulated Expenses' 5-year high stood at $16.8 million during Q4 2023, with a 5-year trough of $7.2 million in Q2 2022.
  • Its 5-year average for Accumulated Expenses is $10.7 million, with a median of $11.0 million in 2021.
  • As far as peak fluctuations go, Voyager Therapeutics' Accumulated Expenses plummeted by 4773.14% in 2021, and later skyrocketed by 11523.8% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Accumulated Expenses stood at $11.0 million in 2021, then dropped by 28.62% to $7.8 million in 2022, then surged by 115.24% to $16.8 million in 2023, then dropped by 15.76% to $14.2 million in 2024, then rose by 5.52% to $15.0 million in 2025.
  • Its Accumulated Expenses was $15.0 million in Q3 2025, compared to $12.0 million in Q2 2025 and $9.1 million in Q1 2025.